151 related articles for article (PubMed ID: 18563070)
1. The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs.
Uppoor RS; Mummaneni P; Cooper E; Pien HH; Sorensen AG; Collins J; Mehta MU; Yasuda SU
Clin Pharmacol Ther; 2008 Jul; 84(1):69-74. PubMed ID: 18563070
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications.
Zhang Y; Zhang L; Abraham S; Apparaju S; Wu TC; Strong JM; Xiao S; Atkinson AJ; Thummel KE; Leeder JS; Lee C; Burckart GJ; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2009 Mar; 85(3):305-11. PubMed ID: 19020495
[TBL] [Abstract][Full Text] [Related]
3. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
Bhattaram VA; Booth BP; Ramchandani RP; Beasley BN; Wang Y; Tandon V; Duan JZ; Baweja RK; Marroum PJ; Uppoor RS; Rahman NA; Sahajwalla CG; Powell JR; Mehta MU; Gobburu JV
AAPS J; 2005 Oct; 7(3):E503-12. PubMed ID: 16353928
[TBL] [Abstract][Full Text] [Related]
4. The application of neuroimaging techniques to drug development.
Tamminga CA; Conley RR
J Clin Psychiatry; 1997; 58 Suppl 10():3-6. PubMed ID: 9265909
[TBL] [Abstract][Full Text] [Related]
5. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
[TBL] [Abstract][Full Text] [Related]
6. New drug approval times and clinical evidence in Japan.
Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
[TBL] [Abstract][Full Text] [Related]
7. PET-based neuropharmacology: state of the art.
Lucignani G; Moresco RM; Fazio F
Cerebrovasc Brain Metab Rev; 1989; 1(4):271-87. PubMed ID: 2701655
[TBL] [Abstract][Full Text] [Related]
8. Clinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures.
Kelly TH; Stoops WW; Perry AS; Prendergast MA; Rush CR
Behav Cogn Neurosci Rev; 2003 Dec; 2(4):227-60. PubMed ID: 15006288
[TBL] [Abstract][Full Text] [Related]
9. In vivo drug-drug interaction studies--a survey of all new molecular entities approved from 1987 to 1997.
Marroum PJ; Uppoor RS; Parmelee T; Ajayi F; Burnett A; Yuan R; Svadjian R; Lesko LJ; Balian JD
Clin Pharmacol Ther; 2000 Sep; 68(3):280-5. PubMed ID: 11014409
[TBL] [Abstract][Full Text] [Related]
10. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
11. Leveraging exploratory investigational new drug studies to accelerate drug development.
Jacobson-Kram D; Mills G
Clin Cancer Res; 2008 Jun; 14(12):3670-4. PubMed ID: 18559581
[TBL] [Abstract][Full Text] [Related]
12. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
[TBL] [Abstract][Full Text] [Related]
13. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
Tanaka M; Nagata T
Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
[TBL] [Abstract][Full Text] [Related]
14. Designing a molecular delivery system within a preclinical timeframe.
Henck JO; Byrn SR
Drug Discov Today; 2007 Mar; 12(5-6):189-99. PubMed ID: 17331883
[TBL] [Abstract][Full Text] [Related]
15. Molecular imaging to select cancer therapy and evaluate treatment response.
Mankoff DA
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):181-92. PubMed ID: 19293766
[TBL] [Abstract][Full Text] [Related]
16. Biomedical imaging in the safety evaluation of new drugs.
Wang YX; Yan SX
Lab Anim; 2008 Oct; 42(4):433-41. PubMed ID: 18782821
[TBL] [Abstract][Full Text] [Related]
17. Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.
Riner A; Chan-Tack KM; Murray JS
Postgrad Med; 2009 May; 121(3):139-46. PubMed ID: 19491552
[TBL] [Abstract][Full Text] [Related]
18. Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies.
Ishibashi T; Kusama M; Sugiyama Y; Ono S
J Clin Pharm Ther; 2012 Dec; 37(6):657-63. PubMed ID: 22734557
[TBL] [Abstract][Full Text] [Related]
19. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
Robinson WT
Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
[TBL] [Abstract][Full Text] [Related]
20. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
